natgillin/translations-raw huggingface dataset:
In humans it is known that itraconazole can inhibit the metabolism of medicinal products that are substrates for cytochrome 3A isoenzymes, for example, chloramphenicol, ivermectin or methylprednisolone.
Poznato je da itrakonazol može u ljudi inhibirati metabolizam lijekova koji su zamjena za izoenzime citokrom 3A, primjerice, kloramfenikol, ivermectin ili metilprednizolon.
In humans, dimethyl fumarate is extensively metabolised by esterases before it reaches the systemic circulation and further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system.
Kod ljudi, esteraze ekstenzivno metaboliziraju dimetilfumarat prije nego što dođe u sistemsku cirkulaciju i daljnji metabolizam kroz ciklus trikarboksilne kiseline, bez posredovanja sustava citokroma P450 (CYP).
In humans, the apparent terminal volume of distribution is at least 90 l and the amount of dose reaching the bone is estimated to be 40 – 50 % of the circulating dose.
U ljudi prividni terminalni volumen distribucije iznosi najmanje 90 l, dok se količina doze koja dospijeva do kosti procjenjuje na 40-50% cirkulirajuće doze.
In humans, the apparent terminal volume of distribution is at least 90 l and the amount of dose reaching the bone is estimated to be 40-50 % of the circulating dose.
U ljudi, prividni terminalni volumen distribucije iznosi najmanje 90 l, dok se količina doze koja dospijeva do kosti procjenjuje na 40-50% cirkulirajuće doze.
In humans, the apparent terminal volume of distribution is at least 90 l and the amount of dose reaching the bone is estimated to be 40-50% of the circulating dose.
U ljudi, prividni terminalni volumen raspodjele iznosi najmanje 90 l, a procjenjuje se da količina doze koja dospijeva do kostiju iznosi oko 40% do 50% cirkulirajuće doze.
In humans, the metabolite N- desethylbrinzolamide is formed, which also binds to CA and accumulates in RBCs.
Kod ljudi nastaje metabolit N-desetil-brinzolamid, koji se veže na CA i akumulira u eritrocitima.
In humans, the most common symptoms associated with overdosage include seizures, somnolence, nausea, tachycardia, and vomiting.
Kod ljudi najčešći simptomi povezani s predoziranjem uključuju napadaje, pospanost, mučninu, tahikardiju i povraćanje.
In humans, the one major circulating metabolite (M1) results from desethylation of vardenafil and is subject to further metabolism with a plasma elimination half-life of approximately 4 hours.
U ljudi, jedini glavni cirkulirajući metabolit (M1) nastaje deetilacijom vardenafila i podliježe daljnjem metabolizmu uz poluvrijeme eliminacije iz plazme od približno 4 sata.
In humans, the protein binding of pramipexole is very low (< 20%) and the volume of distribution is large (400 l).
Kod ljudi pramipeksola se u manjoj mjeri veže na proteine (<20%), ali ima velik volumen distribucije (400 l).
In humans, the protein binding of pramipexole is very low (< 20%) and the volume of distribution is large (400 l).
U ljudi se pramipeksol u manjoj mjeri veže na proteine (<20%), ali ima velik volumen distribucije (400 l).
In humans, the rate and extent of absorption of amifampridine is influenced by food (See Table 2).
U ljudi su brzina i opseg apsorpcije amifampridina pod utjecajem hrane (vidjeti tablicu 2).
In humans, there is no evidence that enoxaparin crosses the placental barrier during the second trimester of pregnancy.
U ljudi nema dokaza da enoksaparin prolazi placentarnu barijeru tijekom drugog tromjesečja trudnoće.
In humans, Thymanax has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.
Kod ljudi, Thymanax ima svojstva pozitivnog mijenjanja faza; izaziva uznapredovalu fazu sna, pad tjelesne temperature i nastup djelovanja melatonina.
In humans, Valdoxan has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.
Kod ljudi, Valdoxan ima svojstva pozitivnog mijenjanja faza; izaziva uznapredovalu fazu sna, pad tjelesne temperature i nastup djelovanja melatonina.
In humans, vardenafil had no effect on bleeding time alone or in combination with acetylsalicyclic acid (see section 4.5).
U ljudi vardenafil sam ili u kombinaciji s acetilsalicilatnom kiselinom nije utjecao na vrijeme krvarenja (vidjeti dio 4.5).
In humans, vardenafil had no effect on bleeding time alone or in combination with acetylsalicylic acid (see section 4.5).
U ljudi vardenafil sam ili u kombinaciji s acetilsalicilatnom kiselinom nije utjecao na vrijeme krvarenja (vidjeti dio 4.5).
In hypertensive patients not controlled by the component monotherapies, once-daily administration of Rasilamlo provided dose-dependent clinically meaningful reductions in both systolic and diastolic blood pressure.
U hipertenzivnih bolesnika u kojih monoterapije komponentama nisu postigle odgovarajuću kontrolu krvnog tlaka primjena lijeka Rasilamlo jednom dnevno dovela je do klinički značajnih, o dozi ovisnih sniženja oba, sistoličkog i dijastoličkog krvnog tlaka.
In hypertensive patients, once-daily administration of Rasilez at doses of 150 mg and 300 mg provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to trough ratio for diastolic response of up to 98% for the 300 mg dose.
U hipertenzivnih bolesnika, primjena Rasileza jedanput dnevnou dozama od 150 mg i 300 mg osigurala je sniženje sistoličkog i dijastoličkog krvnog tlaka ovisno o dozi, koje je održavano tijekom čitavog 24-satnog doznog intervala (održavajući korist u ranim jutarnjim satima) sa srednjom vrijednošću omjera najviše i najniže vrijednosti za dijastolički odgovor do 98% pri dozi od 300 mg.
In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.
U hipertenzivnih bolesnika sa š eć ernom bolesti tipa 2 liječ enje treba započ eti sa 150 mg irbesartana jedanput na dan i dozu titrirati do 300 mg jedanput na dan, š to je doza održ avanja koja se preporuč uje za liječ enje bubrež ne bolesti.
In HZA106827/HZA106829 the co-primary efficacy endpoints were change from baseline in clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at the end of the treatment period in all subjects and weighted mean serial FEV1 over 0-24 hours post-dose calculated in a subset of subjects at the end of the treatment period.
U ispitivanjima HZA106827/HZA106829 dvije primarne mjere ishoda djelotvornosti bile su promjena od početne najniže vrijednosti (prije primjene brohnodilatatora i prije uzimanja lijeka) FEV1 pri kliničkom posjetu na kraju terapijskog razdoblja u svih ispitanika te ponderirana srednja vrijednost FEV1 mjerenog serijski u razdoblju od 0-24 sata nakon uzimanja lijeka, izračunata u podskupini ispitanika na kraju terapijskog razdoblja.
In iliac crest bone biopsies obtained after up to 60 months of treatment with strontium ranelate 2 g/day in phase III trials, no deleterious effects on bone quality or mineralisation were observed.
U materijalu dobivenom biopsijom kriste ilijake nakon terapije stroncijevim ranelatom u dozi od 2 g na dan tijekom razdoblja do 60 mjeseci u sklopu ispitivanja III. faze nije bilo nikakvih znakova štetnih učinaka na kvalitetu ni na mineralizaciju kosti.
In IM-UNITI, 29 of 129 patients did not maintain response to ustekinumab when treated every
U IM-UNITI, kod 29 od 129 bolesnika nije održan odgovor na ustekinumab kod liječenja svakih
In immunocompromised patients, repeat treatment with imiquimod cream is not recommended.
U bolesnika s oslabljenim imunitetom ne preporučuje se ponavljanje liječenja imikvimod kremom.
In IMPACT and IMPACT 2, clinical responses were observed as early as week 2 and were maintained through week 98 and week 54 respectively.
U ispitivanjima IMPACT i IMPACT 2 klinički su odgovor primijećen već u 2. tjednu i održali su se do 98. tjedna u ispitivanju IMPACT odnosno do 54. tjedna u ispitivanju IMPACT 2.
In IMPACT and IMPACT 2, clinical responses were observed as early as week 2 and were maintained through week 98 and week 54 respectively.
U ispitivanjima IMPACT i IMPACT 2 klinički su odgovori primijećeni već u 2. tjednu i održali su se do 98. tjedna u ispitivanju IMPACT odnosno do 54. tjedna u ispitivanju IMPACT 2.
In in the treatment phase of this study, the most prevalent adverse reactions in all subjects were pyrexia (80 %), headache (62 %), neutropenia (33 %), fatigue (30 %), anorexia (29 %) and injection- site erythema (29 %).
U fazi liječenja u sklopu ovoga ispitivanja nuspojave koje su se najčešće pojavljivale u svih ispitanika bile pireksija (80%), glavobolja (62%), neutropenija (33%), umor (30%), anoreksija (29%) i eritem na mjestu injekcije (29%).
In in vitro bio-assays, fluralaner is not affected by proven field resistances against amidines (tick), organophosphates (tick, mite), cyclodienes (tick, flea, fly), macrocyclic lactones (sea lice), phenylpyrazoles (tick, flea), benzophenyl ureas (tick), pyrethroids (tick, mite) and carbamates (mite).
U in-vitro bio-testovima, fluralaner je otporan na dokazanu terensku rezistenciju protiv amidina (krpelji), organofosfata (krpelj, grinje), ciklodina (krpelj, buha, muha), makrocikličkih laktona (morske uši), fenilpirazola (krpelj, buha), benzofenil uree (krpelj), piretroida (krpelj, grinje) i karbamata (grinje).
In in vitro studies in human liver microsomes, temsirolimus inhibited CYP3A4/5, CYP2D6, CYP2C9 and CYP2C8 catalytic activity with Ki values of 3.1, 1.5, 14 and 27 μM, respectively.
U ispitivanjima in vitro na ljudskim jetrenim mikrosomima, temsirolimus je inhibirao katalitičku aktivnost CYP3A4/5, CYP2D6, CYP2C9 i CYP2C8 s vrijednostima Ki od 3,1; 1,5; 14 odnosno 27 μM.
In in vitro studies, bosutinib inhibits proliferation and survival of established CML cell lines, Ph+ acute lymphoblastic leukaemia cell lines, and patient-derived primary primitive CML cells.
U in vitro ispitivanjima bosutinib inhibira proliferaciju i preživljenje odabranih staničnih linija KML- a, staničnih linija Ph+ akutne limfoblastične leukemije i primarnih primitivnih stanica KML-a dobivenih od bolesnika.
In in vitro studies, IC50 values for the serotonin transporter and KATP channels were found to be 7 and 12 fold greater, respectively, than the EC50 for the calcium-sensing receptor obtained under the same experimental conditions.
U in vitro studijama, pod istim eksperimentalnim uvjetima, pronađeno je da su IC50 vrijednosti transportera serotonina i KAT P kanala bile 7, odnosno 12 puta veće nego EC50 za receptore osjetljive na kalcij.
In in vitro studies, IC50 values for the serotonin transporter and KATP channels were found to be 7 and 12 fold greater, respectively, than the EC50 for the calcium-sensing receptor obtained under the same experimental conditions.
U in vitro studijama, pod istim eksperimentalnim uvjetima, pronađeno je da su IC50 vrijednosti transportera serotonina i KATP kanala bile 7, odnosno 12 puta veće nego EC50 za receptore osjetljive na kalcij.
In in vitro studies, ospemifene and 4-hydroxyospemifene did not inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT2, organic anion transporter (OAT)1 or OAT3 at clinically relevant concentrations.
U ispitivanjim in vitro, ospemifen i 4-hidroksiospemifen nisu inhibirali P-glikoprotein (P-gp), protein otpornosti na rak dojke (engl. breast cancer resistance protein - BCRP), polipeptid organskog anionskog prijenosnika (engl. organic anion transporter polypeptide - OATP)1B1, OATP1B3, OCT2, organski anionski prijenosnik (engl. organic anion transporter - OAT)1 ili OAT3 u klinički relevantnim koncentracijama.
In in vitro studies, saxagliptin and its major metabolite neither inhibited CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4, nor induced CYP1A2, 2B6, 2C9, or 3A4.
U in vitro ispitivanjima saksagliptin i njegov glavni metabolit nisu inhibirali CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 i 3A4, niti su inducirali CYP1A2, 2B6, 2C9 i 3A4.
In in vitro studies, the specific activity of lipases for glycerol phenylbutyrate was seen in the following decreasing order: pancreatic triglyceride lipase, carboxyl ester lipase, and pancreatic lipase–related protein 2.
U in vitro ispitivanjima,specifična aktivnost lipaza za glicerolfenilbutirat opažena je ovim padajućim slijedom: trigliceridna lipaza gušterače, karboksil ester lipaza, i protein 2 povezan s lipazom gušterače.
In in-vitro canine whole blood assays, firocoxib exhibited approximately 380-fold selectivity for COX-2 over COX-1.
U in-vitro testiranjima krvi psa, firokoksib pokazuje približno 380 puta veću selektivnost za COX-2 u odnosu na COX-1.
In in-vitro studies ospemifene is a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8 and CYP2D6.
U ispitivanjima in vitro ospemifen je slabi inhibitor CYP2B6, CYP2C9, CYP2C19, CYP2C8 i CYP2D6.
In in-vitro studies, only a small fraction of rufinamide (34%) was bound to human serum proteins with albumin accounting for approximately 80% of this binding.
U ispitivanjima in vitro, samo je mali udio rufinamida (34%) bio vezan za proteine u ljudskom serumu, od čega približno 80% za albumin.
in increments of
tjedna s
In individual cases, so- called ‘neutralising antibodies’ may develop, which may diminish activity of Elaprase and your response to treatment.
U pojedinim slučajevima mogu se razviti takozvana “neutralizirajuća protutijela”, koja mogu smanjiti aktivnost lijeka Elaprase i Vaš odgovor na liječenje.
In individual pigs the temperature increase compared to pre-treatment may commonly exceed 2°C. This resolves spontaneously within 48 hours without treatment.
U pojedinih svinja povećanje temperature u odnosu na onu prije tretmana obično može prijeći 2°C. Ono se spontano povlači unutar 48 sati bez liječenja.
In individual pigs this temperature may increase up to 2 °C. The animals return to normal within 1-2 days after the peak temperature is observed.
Štoviše, uobičajeno je prolazno povećanje tjelesne temperature na dan cijepljenja od oko 0,2°C. U pojedinih svinja ova temperatura može se povećati do 2°C. Temperatura se vraća na normalne vrijednosti unutar 1-2 dana nakon uočene vršne vrijednosti temperature.
In individuals at risk for renal disease more frequent monitoring of renal function is required.
U osoba s rizikom od bubrežne bolesti, bubrežnu funkciju treba kontrolirati češće.
In individuals with an haematopoietic stem cell transplant (HSCT), the recommended immunisation series consists of four doses of Prevenar 13, each of 0.5 ml.
U osoba s presađenim hematopoetskim matičnim stanicama preporučena serija imunizacije sastoji se od četiri doze Prevenara 13 (svaka doza od 0,5 ml).
In individuals with Gaucher disease, glucosylceramide degradation is insufficient, leading to accumulation of large quantities of this substrate within the lysosomes of macrophages (termed ‘Gaucher cells’), leading to widespread secondary pathology.
U osoba s Gaucherovom bolešću razgradnja glukozilceramida je nedostatna te dolazi do nakupljanja velike količine tog supstrata u lizosomima makrofaga (nazvanih "Gaucherove stanice"), što dovodi do rasprostranjene sekundarne patologije.
In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively.
U osoba s blago (klirens kreatinina 50 – 80 ml/min), umjereno (klirens kreatinina 30 – 49 ml/min) i jako (klirens kreatinina 15 – 29 ml/min) oštećenom funkcijom bubrega, koncentracije rivaroksabana u plazmi (AUC) povećale su se, redom, 1,4, 1,5 i 1,6 puta.
In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively.
U osoba s blago (klirens kreatinina 50 – 80 ml/min), umjereno (klirens kreatinina 30 – 49 ml/min) i teško (klirens kreatinina 15 – 29 ml/min) oštećenom funkcijom bubrega, koncentracije rivaroksabana u plazmi (AUC) povećale su se, redom, 1,4, 1,5 i 1,6 puta.
In individuals without risk factors for renal disease, it is recommended that renal function (creatinine clearance and serum phosphate) is monitored after two to four weeks of use, after three months of use and every three to six months thereafter.
U osoba bez čimbenika rizika za bubrežnu bolest preporučuje se kontrolirati funkciju bubrega (klirens kreatinina i fosfate u serumu) nakon dva do četiri tjedna primjene, nakon tri mjeseca primjene i svakih tri do šest mjeseci nakon toga.
In infants and children (age 1–11 years, n=25), the steady-state distribution volume was 4.82.1 l, half-life was 9.54.5 days and clearance was 176 ml/h.
U dojenčadi i djece (dob 1-11 godina, n=25) volumen distribucije u ravnotežnom stanju bio je 4,8±2,1 l, poluvrijeme života bilo je 9,5±4,5 dana, a klirens je bio 17±6 ml/h.
In infants exposed in utero to infliximab, fatal outcome due to disseminated Bacillus Calmette-Guérin (BCG) infection has been reported following administration of BCG vaccine after birth.
U dojenčadi koja je intrauterino bila izložena infliksimabu prijavljen je smrtni ishod zbog diseminirane infekcije Bacillus Calmette-Guérin (BCG) nakon primjene BCG-cjepiva nakon rođenja.
in infants or young children up to 3 years, since NeoRecormon Multidose solvent contains benzyl alcohol as a preservative
u novorođenčadi ili male djece do 3 godine starosti, budući da otapalo lijeka NeoRecormon Multidose sadrži benzilni alkohol kao konzervans.
In infliximab treated subjects, significant PASI 50 responses were apparent at the first visit (week 2) and PASI 75 responses by the second visit (week 6).
U ispitanika liječenih infliksimabom, značajan odgovor PASI 50 bio je vidljiv pri prvoj posjeti liječniku (2. tjedan), a odgovor PASI 75 pri drugoj posjeti (6. tjedan).
In infliximab treated subjects, significant PASI 50 responses were apparent at the first visit (week 2) and PASI 75 responses by the second visit (week 6).
U ispitanika liječenih infliksimabom, značajan odgovor PASI- 50 bio je vidljiv pri prvoj posjeti liječniku (2. tjedan), a odgovor PASI 75 pri drugoj posjeti (6. tjedan).
In influenza-positive older people , oseltamivir significantly reduced the incidence of specified lower respiratory tract complications (mainly bronchitis) treated with antibiotics from 19 % (52/268) in the placebo group to 12 % (29/250) in the oseltamivir treated population (p = 0.0156).
U starijih influenca-pozitivnih osoba oseltamivir je značajno smanjio incidenciju specifičnih komplikacija donjih dišnih putova (uglavnom bronhitisa), koje su se liječile antibioticima s 19 % (52/268) u skupini koja je primala placebo, na 12 % (29/250) u skupini koja je primala oseltamivir (p = 0,0156).
In inhalation studies in rats, the administration of an iloprost formulation with a concentration of
U ispitivanjima inhalacije na štakorima primjena formule iloprosta s koncentracijom od
In initial studies of healthy volunteers, administration of a single dose of posaconazole infused over 30 minutes via a peripheral venous catheter was associated with a 12 % incidence of infusion site reactions (4 % incidence of thrombophlebitis).
U početnim ispitivanjima sa zdravim dobrovoljcima, primjena jednokratne doze posakonazola infuzijom tijekom 30 minuta kroz periferni venski kateter bila je povezana s incidencijom reakcija na mjestu infuzije od 12% (incidencija tromboflebitisa bila je 4%).
In Instanyl, fentanyl is contained inside a nasal spray.
U lijeku Instanyl, fentanil je sadržan unutar spreja za nos.
In insulin glulisine the replacement of the human insulin amino acid asparagine in position B3 by lysine and the lysine in position B29 by glutamic acid favors more rapid absorption.
Zamjena aminokiseline asparagina ljudskog inzulina na poziciji B3 lizinom i lizina na poziciji B29 glutaminskom kiselinom potiče bržu apsorpciju inzulina glulizina.
In insulin infusion pumps.
U inzulinskim infuzijskim pumpama.
In integrated analysis of the 2 studies, the percentage of subjects with 15 letter improvement at Day 14 and maintained to Day 90 was higher in NEVANAC 3 mg/ml group (55.4%) compared to vehicle group (46.7%, p=0.003).
U integriranoj analizi dva ispitivanja, postotak ispitanika sa poboljšanjem od 15 slova u 14. danu i održanim poboljšanjem do 90. dana bio je veći u grupi s lijekom NEVANAC 3mg/ml (55,4%) u usporedbi s grupom koja je primala podlogu lijeka (46,7%, p=0,003).
In integrated Studies I and II, patients receiving reslizumab 3 mg/kg had significant reductions in asthma exacerbations (56% for subgroup GINA 4 and 5) compared to placebo.
U integriranim Ispitivanjima I i II, bolesnici koji su primali reslizumab u dozi od 3 mg/kg imali su značajno smanjenje egzacerbacija astme (56% u podskupini GINA 4 i 5) u usporedbi s onima koji su primali placebo.
In intent to treat analyses, 50% and 57% of patients in the 350 and 450 mg/m2 dose groups, respectively, achieved reduction in plasma HIV-1 RNA to ≤ 400 copies/ml at Week 48.
ITT analiza je pokazala da se broj kopija HIV-1 RNA nakon 48 tjedana smanjio na  400/ml u, redom, 50% i 57
In interaction studies in healthy volunteers, sevelamer hydrochloride decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with Renagel in a single dose study.
U ispitivanjima interakcija u zdravih dobrovoljaca, prilikom istodobne primjene lijeka Renagel i ciprofloksacina u ispitivanju s primjenom jedne doze, sevelamerklorid je smanjio bioraspoloživost ciprofloksacina za približno 50%.
In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as Renvela, decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study.
U ispitivanjima interakcija u zdravih dobrovoljaca prilikom istodobne primjene sevelamerklorida, koji sadrži istu djelatnu tvar kao Renvela, i ciprofloksacina, sevelamerklorid je u ispitivanju s primjenom jedne doze smanjio bioraspoloživost ciprofloksacina za približno 50%.
In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as Renvela, decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study.
U ispitivanjima interakcija u zdravih dobrovoljaca, prilikom istodobne primjene sevelamerklorida, koji sadrži istu djelatnu tvar kao Renvela, i ciprofloksacina, sevelamerklorid je u ispitivanju s primjenom jedne doze smanjio bioraspoloživost ciprofloksacina za približno 50%.
In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as Sevelamer carbonate Zentiva, decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study.
U ispitivanjima interakcija u zdravih dobrovoljaca prilikom istodobne primjene sevelamerklorida, koji sadrži istu djelatnu tvar kao Sevelamer carbonate Zentiva, i ciprofloksacina, sevelamerklorid je u ispitivanju s primjenom jedne doze smanjio bioraspoloživost ciprofloksacina za približno 50%.
In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as Sevelamer carbonate Zentiva, decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study.
U ispitivanjima interakcija u zdravih dobrovoljaca, prilikom istodobne primjene sevelamerklorida, koji sadrži istu djelatnu tvar kao Sevelamer carbonate Zentiva, i ciprofloksacina, sevelamerklorid je u ispitivanju s primjenom jedne doze smanjio bioraspoloživost ciprofloksacina za približno 50%.